Unyango lokuQala lokuLungisa iSifo soHlobo loku-1 lweSifo seswekile

Provention Bio, Inc. today announced that the resubmitted Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals has been considered a complete, class 2 response to the July 2021 action letter by the U.S. Food and Drug Administration (FDA).  The FDA has assigned a user fee…